Figure 1.

Approved antiretroviral regimens in the past decade (2010 to present). Most combination regimens are composed of two HIV nucleoside/nucleotide reverse transcriptase inhibitors plus one integrase inhibitor, one non-nucleoside reverse transcriptase inhibitor, or one protease inhibitor. Dapivirine vaginal ring 25 mg was approved by the European Medicines Agency on 24 July 2020, while the other regimens have been (tentatively) approved by the FDA.